Tanner Felix C, Largiadèr Thomas, Greutert Helen, Yang Zhihong, Lüscher Thomas F
Cardiovascular Research, Clinic for Cardiovascular Surgery, Department of Clinical Research, University Hospital, Bern, Switzerland.
J Thorac Cardiovasc Surg. 2004 Jan;127(1):20-6. doi: 10.1016/j.jtcvs.2003.07.021.
Bypass graft disease is related to proliferation and migration of vascular smooth muscle cells and to platelet activation with thrombus formation. Nitric oxide inhibits these biological responses; it has never been demonstrated, however, whether this occurs in intact human vascular tissue after endothelial nitric oxide synthase gene transfer.
We examined whether endothelial nitric oxide synthase overexpression inhibits biological features of bypass graft disease in saphenous vein tissue.
The nitric oxide donor diethylenetriamineNONOate inhibited proliferation (P <.001) and migration (P <.001) of human saphenous vein vascular smooth muscle cells in response to 20% serum in a concentration-dependent manner. A similar effect on proliferation (P <.05) and migration (P <.05) without any cytotoxicity was observed after adenoviral endothelial nitric oxide synthase transfection. Staining of saphenous vein tissue for placental alkaline phosphatase demonstrated that adenoviral transfection was efficient. Consistent with this observation, endothelial nitric oxide synthase protein expression and nitric oxide release were enhanced in transfected tissue. Further, endothelial nitric oxide synthase overexpression inhibited vascular smooth muscle cell outgrowth from saphenous vein explants over 21 days; 48% +/- 12% of explants exhibited outgrowth after treatment with endothelial nitric oxide synthase adenovirus as compared with 69% +/- 10% in those infected with control adenovirus and 90% +/- 5% in uninfected tissue (P <.05). Similarly, platelet adhesion to human saphenous vein tissue was inhibited by endothelial nitric oxide synthase overexpression; adhesion was reduced in segments infected with endothelial nitric oxide synthase adenovirus (58% +/- 6%) as compared with those infected with control adenovirus (107% +/- 8%) or uninfected saphenous vein (100%; P <.05).
These data demonstrate that endothelial nitric oxide synthase gene transfer inhibits biological features of bypass graft disease in intact human saphenous vein tissue. Therefore, endothelial nitric oxide synthase transfection represents a promising gene transfer approach to prevent venous bypass graft disease.
旁路移植血管病变与血管平滑肌细胞的增殖和迁移以及血小板激活并形成血栓有关。一氧化氮可抑制这些生物学反应;然而,内皮型一氧化氮合酶基因转移后,在完整的人体血管组织中是否会发生这种情况尚未得到证实。
我们研究了内皮型一氧化氮合酶的过表达是否会抑制大隐静脉组织中旁路移植血管病变的生物学特征。
一氧化氮供体二乙三胺 NONO 酸盐以浓度依赖的方式抑制人隐静脉血管平滑肌细胞对 20%血清的增殖反应(P <.001)和迁移反应(P <.001)。腺病毒介导的内皮型一氧化氮合酶转染后,观察到对增殖(P <.05)和迁移(P <.05)有类似影响,且无任何细胞毒性。大隐静脉组织胎盘碱性磷酸酶染色显示腺病毒转染有效。与此观察结果一致,转染组织中内皮型一氧化氮合酶蛋白表达和一氧化氮释放增强。此外,内皮型一氧化氮合酶的过表达在 21 天内抑制了大隐静脉外植体中血管平滑肌细胞的生长;用内皮型一氧化氮合酶腺病毒处理后,48%±12%的外植体出现生长,而感染对照腺病毒的外植体为 69%±10%,未感染组织为 90%±5%(P <.05)。同样,内皮型一氧化氮合酶的过表达抑制了血小板对人隐静脉组织的黏附;与感染对照腺病毒的节段(107%±8%)或未感染的大隐静脉(100%)相比,感染内皮型一氧化氮合酶腺病毒的节段黏附减少(58%±6%;P <.05)。
这些数据表明,内皮型一氧化氮合酶基因转移抑制了完整人隐静脉组织中旁路移植血管病变的生物学特征。因此,内皮型一氧化氮合酶转染是一种有前景的基因转移方法,可用于预防静脉旁路移植血管病变。